drugset / Trial / NCT06016179
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
Phase 1
Recruiting
12 enrolled
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.
Timeline
- Start
- 2024-01-30
- Primary completion
- 2026-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 50 ug/ml | Other |